# A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

> **NCT06361875** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 910 (actual)

## Conditions studied

- Influenza Immunization

## Interventions

- **BIOLOGICAL:** Quadrivalent Influenza mRNA Vaccine MRT5421
- **BIOLOGICAL:** Quadrivalent Influenza mRNA Vaccine MRT5424
- **BIOLOGICAL:** Quadrivalent Influenza mRNA Vaccine MRT5429
- **BIOLOGICAL:** Quadrivalent Influenza Standard Dose Vaccine
- **BIOLOGICAL:** Quadrivalent Influenza High-Dose Vaccine
- **BIOLOGICAL:** Quadrivalent Recombinant Influenza Vaccine

## Key facts

- **NCT ID:** NCT06361875
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-01
- **Primary completion:** 2025-06-09
- **Final completion:** 2025-06-09
- **Target enrollment:** 910 (ACTUAL)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06361875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06361875, "A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above". Retrieved via AI Analytics 2026-06-27 from https://api.ai-analytics.org/clinical/NCT06361875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*